These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20410685)

  • 1. Targeting the MYCN effector, FAK, in neuroblastoma.
    Davidoff AM
    Cell Cycle; 2010 Mar; 9(6):1026. PubMed ID: 20410685
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
    Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
    Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCN, neuroblastoma and focal adhesion kinase (FAK).
    Beierle EA
    Front Biosci (Elite Ed); 2011 Jan; 3(2):421-33. PubMed ID: 21196322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma.
    Waters AM; Beierle EA
    Anticancer Agents Med Chem; 2014 Jan; 14(1):46-51. PubMed ID: 24041229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FAK is a critical regulator of neuroblastoma liver metastasis.
    Lee S; Qiao J; Paul P; O'Connor KL; Evers MB; Chung DH
    Oncotarget; 2012 Dec; 3(12):1576-87. PubMed ID: 23211542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting focal adhesion kinase in neuroblastoma.
    Gillory L; Beierle EA
    Anticancer Agents Med Chem; 2010 Dec; 10(10):714-21. PubMed ID: 21269252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the relationship between n-myc and Focal Adhesion Kinase (FAK) in neuroblastoma?
    Madonna MB
    Cell Cycle; 2010 May; 9(9):1679-80. PubMed ID: 20448460
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
    Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
    J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
    Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
    Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
    Ham J; Costa C; Sano R; Lochmann TL; Sennott EM; Patel NU; Dastur A; Gomez-Caraballo M; Krytska K; Hata AN; Floros KV; Hughes MT; Jakubik CT; Heisey DA; Ferrell JT; Bristol ML; March RJ; Yates C; Hicks MA; Nakajima W; Gowda M; Windle BE; Dozmorov MG; Garnett MJ; McDermott U; Harada H; Taylor SM; Morgan IM; Benes CH; Engelman JA; Mossé YP; Faber AC
    Cancer Cell; 2016 Feb; 29(2):159-72. PubMed ID: 26859456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugging MYCN through an allosteric transition in Aurora kinase A.
    Gustafson WC; Meyerowitz JG; Nekritz EA; Chen J; Benes C; Charron E; Simonds EF; Seeger R; Matthay KK; Hertz NT; Eilers M; Shokat KM; Weiss WA
    Cancer Cell; 2014 Sep; 26(3):414-427. PubMed ID: 25175806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
    Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
    Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model.
    Blanc E; Goldschneider D; Ferrandis E; Barrois M; Le Roux G; Leonce S; Douc-Rasy S; Bénard J; Raguénez G
    Am J Pathol; 2003 Jul; 163(1):321-31. PubMed ID: 12819037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK pERKs up MYCN in neuroblastoma.
    Lindner S; Henssen A; Astrahantseff K; Schulte JH
    Sci Signal; 2014 Oct; 7(349):pe27. PubMed ID: 25351246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting MYCN: a good BET for improving neuroblastoma therapy?
    Schnepp RW; Maris JM
    Cancer Discov; 2013 Mar; 3(3):255-7. PubMed ID: 23475876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
    Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.